Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blue Fin Group provides commercialization strategy and consulting services to pharmaceutical and life sciences companies across all therapeutic areas and product types. They have supported launches for cell and gene therapies, orphan/rare disease products, specialty medicines, biosimilars, generics, vaccines, and more. Their expertise includes market access optimization, gross-to-net management strategies, channel design/optimization, patient support program design, pricing/policy analysis and long-range commercial planning.
The company was acquired by IntegriChain in January 2022 but continues to operate under its own brand as a specialized consultancy within the parent organization.
They do not conduct clinical trials or have their own drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Blue Fin Group.